Cargando…
Factor VII, EPCR, aPC Modulators: novel treatment for neuroinflammation
BACKGROUND: Inflammation and coagulation are linked and pathogenic in neuroinflammatory diseases. Protease-activated receptor 1 (PAR1) can be activated both by thrombin, inducing increased inflammation, and activated protein C (aPC), inducing decreased inflammation. Modulation of the aPC-PAR1 pathwa...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187898/ https://www.ncbi.nlm.nih.gov/pubmed/35690769 http://dx.doi.org/10.1186/s12974-022-02505-y |
_version_ | 1784725257488171008 |
---|---|
author | Golderman, Valery Ben-Shimon, Marina Maggio, Nicola Dori, Amir Gofrit, Shany Guly Berkowitz, Shani Qassim, Lamis Artan-Furman, Avital Zeimer, Talya Chapman, Joab Shavit-Stein, Efrat |
author_facet | Golderman, Valery Ben-Shimon, Marina Maggio, Nicola Dori, Amir Gofrit, Shany Guly Berkowitz, Shani Qassim, Lamis Artan-Furman, Avital Zeimer, Talya Chapman, Joab Shavit-Stein, Efrat |
author_sort | Golderman, Valery |
collection | PubMed |
description | BACKGROUND: Inflammation and coagulation are linked and pathogenic in neuroinflammatory diseases. Protease-activated receptor 1 (PAR1) can be activated both by thrombin, inducing increased inflammation, and activated protein C (aPC), inducing decreased inflammation. Modulation of the aPC-PAR1 pathway may prevent the neuroinflammation associated with PAR1 over-activation. METHODS: We synthesized a group of novel molecules based on the binding site of FVII/aPC to the endothelial protein C receptor (EPCR). These molecules modulate the FVII/aPC-EPCR pathway and are therefore named FEAMs—Factor VII, EPCR, aPC Modulators. We studied the molecular and behavioral effects of a selected FEAM in neuroinflammation models in-vitro and in-vivo. RESULTS: In a lipopolysaccharide (LPS) induced in-vitro model, neuroinflammation leads to increased thrombin activity compared to control (2.7 ± 0.11 and 2.23 ± 0.13 mU/ml, respectively, p = 0.01) and decreased aPC activity (0.57 ± 0.01 and 1.00 ± 0.02, respectively, p < 0.0001). In addition, increased phosphorylated extracellular regulated kinase (pERK) (0.99 ± 0.13, 1.39 ± 0.14, control and LPS, p < 0.04) and protein kinase B (pAKT) (1.00 ± 0.09, 2.83 ± 0.81, control and LPS, p < 0.0002) levels indicate PAR1 overactivation, which leads to increased tumor necrosis factor-alpha (TNF-α) level (1.00 ± 0.04, 1.35 ± 0.12, control and LPS, p = 0.02). In a minimal traumatic brain injury (mTBI) induced neuroinflammation in-vivo model in mice, increased thrombin activity, PAR1 activation, and TNF-α levels were measured. Additionally, significant memory impairment, as indicated by a lower recognition index in the Novel Object Recognition (NOR) test and Y-maze test (NOR: 0.19 ± 0.06, -0.07 ± 0.09, p = 0.03. Y-Maze: 0.50 ± 0.03, 0.23 ± 0.09, p = 0.02 control and mTBI, respectively), as well as hypersensitivity by hot-plate latency (16.6 ± 0.89, 12.8 ± 0.56 s, control and mTBI, p = 0.01), were seen. FEAM prevented most of the molecular and behavioral negative effects of neuroinflammation in-vitro and in-vivo, most likely through EPCR-PAR1 interactions. CONCLUSION: FEAM is a promising tool to study neuroinflammation and a potential treatment for a variety of neuroinflammatory diseases. |
format | Online Article Text |
id | pubmed-9187898 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-91878982022-06-12 Factor VII, EPCR, aPC Modulators: novel treatment for neuroinflammation Golderman, Valery Ben-Shimon, Marina Maggio, Nicola Dori, Amir Gofrit, Shany Guly Berkowitz, Shani Qassim, Lamis Artan-Furman, Avital Zeimer, Talya Chapman, Joab Shavit-Stein, Efrat J Neuroinflammation Research BACKGROUND: Inflammation and coagulation are linked and pathogenic in neuroinflammatory diseases. Protease-activated receptor 1 (PAR1) can be activated both by thrombin, inducing increased inflammation, and activated protein C (aPC), inducing decreased inflammation. Modulation of the aPC-PAR1 pathway may prevent the neuroinflammation associated with PAR1 over-activation. METHODS: We synthesized a group of novel molecules based on the binding site of FVII/aPC to the endothelial protein C receptor (EPCR). These molecules modulate the FVII/aPC-EPCR pathway and are therefore named FEAMs—Factor VII, EPCR, aPC Modulators. We studied the molecular and behavioral effects of a selected FEAM in neuroinflammation models in-vitro and in-vivo. RESULTS: In a lipopolysaccharide (LPS) induced in-vitro model, neuroinflammation leads to increased thrombin activity compared to control (2.7 ± 0.11 and 2.23 ± 0.13 mU/ml, respectively, p = 0.01) and decreased aPC activity (0.57 ± 0.01 and 1.00 ± 0.02, respectively, p < 0.0001). In addition, increased phosphorylated extracellular regulated kinase (pERK) (0.99 ± 0.13, 1.39 ± 0.14, control and LPS, p < 0.04) and protein kinase B (pAKT) (1.00 ± 0.09, 2.83 ± 0.81, control and LPS, p < 0.0002) levels indicate PAR1 overactivation, which leads to increased tumor necrosis factor-alpha (TNF-α) level (1.00 ± 0.04, 1.35 ± 0.12, control and LPS, p = 0.02). In a minimal traumatic brain injury (mTBI) induced neuroinflammation in-vivo model in mice, increased thrombin activity, PAR1 activation, and TNF-α levels were measured. Additionally, significant memory impairment, as indicated by a lower recognition index in the Novel Object Recognition (NOR) test and Y-maze test (NOR: 0.19 ± 0.06, -0.07 ± 0.09, p = 0.03. Y-Maze: 0.50 ± 0.03, 0.23 ± 0.09, p = 0.02 control and mTBI, respectively), as well as hypersensitivity by hot-plate latency (16.6 ± 0.89, 12.8 ± 0.56 s, control and mTBI, p = 0.01), were seen. FEAM prevented most of the molecular and behavioral negative effects of neuroinflammation in-vitro and in-vivo, most likely through EPCR-PAR1 interactions. CONCLUSION: FEAM is a promising tool to study neuroinflammation and a potential treatment for a variety of neuroinflammatory diseases. BioMed Central 2022-06-11 /pmc/articles/PMC9187898/ /pubmed/35690769 http://dx.doi.org/10.1186/s12974-022-02505-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Golderman, Valery Ben-Shimon, Marina Maggio, Nicola Dori, Amir Gofrit, Shany Guly Berkowitz, Shani Qassim, Lamis Artan-Furman, Avital Zeimer, Talya Chapman, Joab Shavit-Stein, Efrat Factor VII, EPCR, aPC Modulators: novel treatment for neuroinflammation |
title | Factor VII, EPCR, aPC Modulators: novel treatment for neuroinflammation |
title_full | Factor VII, EPCR, aPC Modulators: novel treatment for neuroinflammation |
title_fullStr | Factor VII, EPCR, aPC Modulators: novel treatment for neuroinflammation |
title_full_unstemmed | Factor VII, EPCR, aPC Modulators: novel treatment for neuroinflammation |
title_short | Factor VII, EPCR, aPC Modulators: novel treatment for neuroinflammation |
title_sort | factor vii, epcr, apc modulators: novel treatment for neuroinflammation |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187898/ https://www.ncbi.nlm.nih.gov/pubmed/35690769 http://dx.doi.org/10.1186/s12974-022-02505-y |
work_keys_str_mv | AT goldermanvalery factorviiepcrapcmodulatorsnoveltreatmentforneuroinflammation AT benshimonmarina factorviiepcrapcmodulatorsnoveltreatmentforneuroinflammation AT maggionicola factorviiepcrapcmodulatorsnoveltreatmentforneuroinflammation AT doriamir factorviiepcrapcmodulatorsnoveltreatmentforneuroinflammation AT gofritshanyguly factorviiepcrapcmodulatorsnoveltreatmentforneuroinflammation AT berkowitzshani factorviiepcrapcmodulatorsnoveltreatmentforneuroinflammation AT qassimlamis factorviiepcrapcmodulatorsnoveltreatmentforneuroinflammation AT artanfurmanavital factorviiepcrapcmodulatorsnoveltreatmentforneuroinflammation AT zeimertalya factorviiepcrapcmodulatorsnoveltreatmentforneuroinflammation AT chapmanjoab factorviiepcrapcmodulatorsnoveltreatmentforneuroinflammation AT shavitsteinefrat factorviiepcrapcmodulatorsnoveltreatmentforneuroinflammation |